← back to search

Scott D. Lee

University of Washington · US
Area of research
Genetics · Epidemiology
Research interest
Research interests include Inflammatory Bowel Disease, Microscopic Colitis, Eosinophilic Esophagitis, and Autoimmune and Inflammatory Disorders.
h-index
33
citations
5,690
works
219
NIH funding
primary concept
email

Recent publications

Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Inflammatory Bowel Diseases 2024cited by 51position: middledoi
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Inflammatory Bowel Diseases 2024cited by 23position: middledoi
A Comparative Evaluation of the Measurement Properties of Three Histological Indices of Mucosal Healing in Ulcerative Colitis: Geboes Score, Robarts Histopathology Index and Nancy Index
Journal of Crohn s and Colitis 2023cited by 37position: middledoi
Differentiation of brain and retinal organoids from confluent cultures of pluripotent stem cells connected by nerve-like axonal projections of optic origin
Stem Cell Reports 2022cited by 48position: middledoi
Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis
Gastroenterology 2019cited by 225position: middledoi
Improving Community Health Worker performance by using a personalised feedback dashboard for supervision: a randomised controlled trial
Journal of Global Health 2018cited by 92position: middledoi
A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn’s Disease
Journal of Crohn s and Colitis 2018cited by 50position: middledoi
Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study
Gut 2017cited by 107position: middledoi
Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol
Inflammatory Bowel Diseases 2017cited by 24position: middledoi
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
New England Journal of Medicine 2016cited by 1,779position: middledoi
Briakinumab for Treatment of Crohnʼs Disease
Inflammatory Bowel Diseases 2015cited by 76position: middledoi
A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
Clinical Gastroenterology and Hepatology 2014cited by 298position: middledoi
Placental Transfer of Anti–Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel Disease
Clinical Gastroenterology and Hepatology 2012cited by 490position: middledoi
Prospective study of the progression of low-grade dysplasia in ulcerative colitis using current cancer surveillance guidelines
Inflammatory Bowel Diseases 2012cited by 65position: middledoi

Grants

Cellular Organization in the Forebrain of a Novel Neurological Mutant
NSF9421555$49,9891994–1996PIRePORTER
The Role of Multiple Adenosine Receptors in the CNS
NSF9196069$64,8001991–1992PIRePORTER
The Role of Multiple Adenosine Receptors in the CNS
NSF8901154$17,8431989–1991PIRePORTER

Frequent collaborators

Corey A. Siegel · Dartmouth–Hitchcock Medical Center5 papers (2012–2024)William J. Sandborn · Mirati Therapeutics (United States)4 papers (2015–2019)Remo Panaccione · Nutrition-Génétique et Exposition aux Risques Environnementaux3 papers (2015–2024)Séverine Vermeire · Europe Hospitals3 papers (2019–2024)Marla C. Dubinsky · Takeda (Japan)3 papers (2012–2024)Laurent Peyrin‐Biroulet · Hôpital Lapeyronie3 papers (2019–2024)Geert D’Haens · Vrije Universiteit Amsterdam3 papers (2017–2024)Stefan Schreiber · Nutrition-Génétique et Exposition aux Risques Environnementaux3 papers (2017–2018)John F. Valentine · University of Utah Health Care2 papers (2012–2015)Douglas C. Wolf · Atlanta Gastroenterology Associates2 papers (2012–2017) · 2 papers (2024–2024) · 2 papers (2024–2024)María T. Abreu · Umeå University2 papers (2012–2024) · 2 papers (2024–2024)Bruce E. Sands · Seattle University2 papers (2024–2024)Peter M. Irving · Guy's and St Thomas' NHS Foundation Trust2 papers (2024–2024) · 2 papers (2024–2024)Tadakazu Hisamatsu · Nippon Kayaku (Japan)2 papers (2024–2024)Brian G. Feagan · Western University2 papers (2015–2017)David T. Rubin · University of California System2 papers (2012–2023)